Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...
After a slow week last week, big rounds saw a good rebound with seven startups raising $100 million or more. While food ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...
The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...
with a readout expected before the end of the year. Other players include Metsera, a newly emerged weight loss biotech that ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Metsera, already a well-funded ...
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024. Leap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback